Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH Mar 23, 2026 6:00 AM Eastern Daylight Time Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH Share ISS Cites Compelling Strategic Rationale, Favorable Market Reaction, and Strong Institutional Confidence in Recommending Shareholders Vote FOR the Transaction Resolution TORONTO--(BUSINES ...

Core Insights - Organigram Global Inc. is launching SHRED Shotz, a 65ml cannabis beverage utilizing its FAST™ nanoemulsion technology for a rapid 15-minute onset [1][1][1] Company Overview - Organigram is recognized as Canada's leading cannabis company by market share [1][1][1] - The launch of SHRED Shotz aligns with the company's strategy of differentiated innovation [1][1][1] - SHRED is one of the company's most successful brands, indicating strong market presence and consumer recognition [1][1][1]

Core Insights - Organigram Global Inc. has launched SHRED Shotz, a 65ml cannabis beverage utilizing its FAST™ nanoemulsion technology for a rapid 15-minute onset [1][1][1] Company Overview - Organigram is recognized as Canada's leading cannabis company by market share [1][1][1] - The launch of SHRED Shotz demonstrates the company's commitment to innovative product offerings [1][1][1]

Group 1 - Organigram Global Inc. (NASDAQ:OGI) is recognized as one of the best pot stocks to buy according to hedge funds, with 7 hedge funds holding stakes in the company as of Q3 2025 [5] - Canaccord raised its price target for Organigram to C$4 from C$3 while maintaining a Buy rating, indicating improved market outlook [2][8] - The company announced a subscription agreement with BT DE Investments, a subsidiary of British American Tobacco, for the acquisition of Sanity Group, which includes a subscription for 14,027,074 shares at C$3.00 per share, totaling approximately C$65.2 million [3] Group 2 - Organigram is expanding its international portfolio by launching Edison and BOXHOT medical cannabis vape and pastille SKUs in Australia, enhancing its product mix and market penetration [4] - Founded in 2013 and headquartered in Moncton, New Brunswick, Organigram focuses on innovation, branded cannabis products, and international expansion [5]

Industry Overview - The global cannabis industry is experiencing a structural transformation due to expanding legalization for both medical and adult use across various regions, with projections suggesting the market could approach $100 billion by 2026 and potentially exceed $400 billion by 2030 [2][4]. - Growth drivers include expanding legalization, rising medical adoption, and the development of ancillary services, with industrial hemp contributing to the sector's addressable market [3][5]. - A proposed reclassification of marijuana by the Drug Enforcement Administration from Schedule I to Schedule III could significantly enhance industry fundamentals by easing tax burdens and improving access to banking services [6][3]. Investment Landscape - Investing in cannabis stocks is viewed as a long-term bet on the normalization of a previously illicit industry transitioning into a regulated market, with the potential for high returns [4][5]. - The sector offers diverse investment pathways, including multi-state operators, ancillary service providers, biotech firms, and diversified ETFs, with many cannabis equities currently at attractive valuation levels following a downturn [7][8]. - Notable risks include high volatility, regulatory uncertainty, and competition from illicit markets, necessitating careful stock selection and a long-term investment horizon [8]. Company Highlights Aurora Cannabis Inc. (NASDAQ: ACB) - Aurora Cannabis is recognized as a leading medical cannabis operator in Canada, with a strategic pivot towards a medical-first model enabling expansion into higher-margin international markets [12][13]. - The company reported Q3 fiscal 2026 results, forecasting global medical cannabis net revenue growth of 10%-15% to $269-$281 million, with medical revenue constituting approximately 81% of total net revenue [13][14]. - Aurora has filed an at-the-market program for up to $100 million to fund initiatives such as cultivation expansion and M&A, closing the quarter with $154 million in cash and no cannabis-related debt [14][15]. Organigram Global Inc. (NASDAQ: OGI) - Organigram has received a price target increase to C$4 from C$3, maintaining a Buy rating, following a subscription agreement with British American Tobacco for a capital infusion of approximately C$65.2 million [16][17]. - The company is expanding its international portfolio with the launch of new medical cannabis products in Australia, reflecting a broadened product mix and deeper market penetration [18][19]. - Organigram is focused on innovation and international expansion, with 7 hedge funds holding stakes in the company as of Q3 2025, positioning it among the best pot stocks to buy according to hedge funds [19].

Core Insights - Marijuana stocks present diverse investment opportunities despite their volatility, with multi-state operators (MSOs) and companies directly involved with cannabis capturing significant market share [1][2] - Ancillary companies providing services and products to cannabis producers are also emerging as viable investment options, indicating a broadening landscape for legal cannabis investments [2] - Positive speculation surrounds the future of legal cannabis, prompting investors to seek promising marijuana stocks for potential substantial returns [3] Company Highlights - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026 [4][7] - **SNDL Inc.**: Focuses on the production and sale of cannabis products for the adult-use market in Canada. The company is set to report its Q4 2025 and full-year results on March 12, 2026, followed by a conference call [8][11] - **Organigram Global Inc.**: Involved in the production and sale of cannabis products in Canada. The company announced the launch of medical vapes and pastilles in Australia, marking a significant step in its international expansion [11][12]

Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia-# Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in AustraliaShare---Launch aligns with rising Australian demand for alternatives to flower and strengthens Organigram's global medical cannabis presenceTORONTO--([BUSINESS WIRE])- -Organigram Global Inc. ("Organigram†or the "Company†) today announced the expansion of its international ...

Core Insights - The cannabis industry is experiencing a resurgence, highlighted by Organigram's acquisition of Sanity Group for up to €250 million (approximately $295 million) [2][3] - This acquisition allows Organigram to establish a presence in the European market, particularly as more countries consider easing cannabis regulations [3][4] - The deal is significant within the European cannabis sector, especially in healthcare, marking one of the largest transactions of its kind in Germany [5] Company Developments - Organigram's stock rose nearly 10% following the announcement, although it remains down about 20% for the year [4] - The company plans to utilize Sanity Group's Berlin infrastructure as a base for European expansion, including pilot projects in Switzerland and potential commercial sales in Germany [4][6] - The acquisition is seen as a strategic move to enhance Organigram's competitive position against rivals like Aurora Cannabis [7] Market Context - Germany's legalization of cannabis in 2024 through a social club model is expected to create a market projected to reach €4.5 billion by 2028 [6] - Sanity Group, as the largest German medical cannabis producer, reported a revenue increase of over three times from 2024 to 2025, reaching €60 million [6] - Canadian cannabis firms are increasingly focusing on international markets where cannabis is legal, rather than the U.S. market, which remains federally illegal [8]

Core Viewpoint - Organigram is set to acquire Sanity Group, a leading German cannabis company, to enhance its position in the global cannabis market, particularly in Europe, which is experiencing rapid growth in both medical and recreational cannabis sectors [1][2]. Acquisition Details - The acquisition will involve an upfront payment of €113.4 million, consisting of €80 million in cash and €33.4 million in Organigram shares, with an additional earnout of up to €113.8 million based on Sanity's financial performance [1][3]. - The share price for the upfront consideration is set at C$3.00, representing a 71% premium over the closing price of C$1.75 on February 17, 2026 [1][3]. - The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and shareholder consent [3][4]. Financial Performance of Sanity Group - Sanity Group's annual net revenue grew from €9 million in 2023 to €60 million in 2025, with €19 million generated in Q4 2025 alone [1][2]. - The company has improved its gross margin from 15% in 2023 to 47% in 2025, indicating strong operational efficiency [1][2]. - The German medical cannabis market, where Sanity operates, was valued at over €2 billion in 2025 and is projected to exceed €4.5 billion by 2028, with a 50% year-over-year growth rate [1][2]. Strategic Rationale - The acquisition will allow Organigram to leverage Sanity's established presence in Europe, enhancing its ability to sell higher-margin products and capture more value in the cannabis supply chain [1][2]. - Sanity's expertise in navigating European regulatory frameworks will be critical as Organigram expands its footprint in new markets, including the UK and Poland [1][2]. - The combined entity will strengthen Organigram's competitive edge in the world's largest federally legal cannabis markets, positioning it as a leader in both Canada and Germany [2][3]. Funding and Financial Structure - The cash component of the acquisition will be financed through a combination of cash on hand, a new credit facility, and a C$65.2 million equity investment from British American Tobacco (BAT) [1][3]. - Organigram has secured a senior secured credit facility of up to $60 million to support the acquisition and related expenses [3][4]. - The earnout consideration will be contingent on Sanity achieving specific financial performance metrics, ensuring that the acquisition is financially accretive [2][3].

Core Insights - Organigram Global Inc. (NASDAQ:OGI) is recognized as one of the top cannabis stocks to invest in currently [1] - The company reported Q1 revenue of $97.3 million, surpassing the consensus estimate of $73.15 million, with an adjusted EBITDA of $5.3 million, up from $1.4 million year-over-year [2] - The growth in revenue and profits is attributed to higher flower yields, synergies from the Motif integration, increased international sales, and improved operational efficiency [2] - Canaccord initiated coverage of OGI with a price target of C$3 and a Buy rating, highlighting the Canadian cannabis market as a global benchmark despite existing challenges [3] Financial Performance - Q1 revenue reached $97.3 million, exceeding the consensus of $73.15 million [2][7] - Adjusted EBITDA increased to $5.3 million from $1.4 million in the previous year, indicating significant profit growth [2] Market Position and Strategy - Organigram is a market leader in pre-rolls, extracts, and milled flower, and is transitioning to a globally integrated, vertically integrated cannabis corporation [3] - The company aims to expand its global presence through international business alliances [4]